A Phase 4 interventional study of Omeprazole 40 mg and Luliconazole Cream 1% in Tinea Pedis and Tinea Cruris, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Tinea Pedis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Tinea Pedis · United States.
Among the 30 studies in Tinea Pedis with a site in United States, this one is the 29th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 4, and was the 20th registered.
73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.
Browse Tinea Pedis studies →1 of the 30 studies in Tinea Pedis with a site in United States is open now. Recruiting first, the newest first:
Propedix, Inc. · Sites in United States
Ages 16+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Tinea Pedis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 128 across 66 interventional studies indexed under Tinea Pedis.
Median enrollment 160 across the 29 interventional studies, 50 across the 1 observational. Of the 27 that completed or were terminated, 11 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
Bausch Health Companies Inc. has 4 studies filed under Tinea Pedis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Tinea Pedis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea pedis and tinea cruris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
Drug: Omeprazole 40 mg · Drug: Luliconazole Cream 1%
Oral capsule to be taken as per the instructions regarding proper dosing technique.
Topical cream to be applied as per the instructions regarding proper study drug application technique.
Also known as: LUZU Cream 1%
Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1%
Circulating plasma levels of omeprazole were measured using validated liquid chromatography with tandem mass spectrometry detection (LS/MS-MS) methods. The range for omeprazole determination was 4.64-9.27 nanograms/milliliter (ng/mL). Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 1) with omeprazole (before the start of luliconazole cream 1% treatment on Day 2).
Time frame: 15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 1
Circulating Levels (Plasma Concentration) of Omeprazole After 1 Week of Treatment With Luliconazole Cream 1%
Circulating plasma levels of omeprazole were measured using validated LS/MS-MS methods. The range for omeprazole determination was 4.64-9.27 ng/mL. Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 8) with omeprazole (after using luliconazole cream 1% treatment for 1 week).
Time frame: 15 minutes predose; 15, 30, 45, and 60 minutes postdose; and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose of omeprazole on Day 8
| Milestone | Luliconazole Cream 1% |
|---|---|
| Started | 20 |
| Received at least 1 dose of study drug | 20 |
| Completed | 18 |
| Not completed | 2 |
| Withdrew: Failed drug screen test | 1 |
| Withdrew: Adverse event | 1 |
Circulating plasma levels of omeprazole were measured using validated liquid chromatography with tandem mass spectrometry detection (LS/MS-MS) methods. The range for omeprazole determination was 4.64-9.27 nanograms/milliliter (ng/mL). Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 1) with omeprazole (before the start of luliconazole cream 1% treatment on Day 2).
| ng/mL | Luliconazole Cream 1% |
|---|---|
| Predose | 0 ± 0 |
| 15 minutes postdose | 0 ± 0 |
| 30 minutes postdose | 23.67 ± 89.46 |
| 45 minutes postdose | 196.30 ± 301.31 |
| 1 hour postdose | 463.74 ± 546.51 |
| 1.5 hours postdose | 526.98 ± 499.60 |
| 2 hours postdose | 655.70 ± 520.31 |
| 2.5 hours postdose | 621.08 ± 464.55 |
| 3 hours postdose | 636.60 ± 508.53 |
| 4 hours postdose | 468.79 ± 355.49 |
| 6 hours postdose | 235.20 ± 214.29 |
| 8 hours postdose | 129.70 ± 129.08 |
| 10 hours postdose | 74.24 ± 84.54 |
| 24 hours postdose | 3.32 ± 6.18 |
Circulating plasma levels of omeprazole were measured using validated LS/MS-MS methods. The range for omeprazole determination was 4.64-9.27 ng/mL. Serial blood sampling occurred in each enrolled participant up to 24 hours post treatment (Day 8) with omeprazole (after using luliconazole cream 1% treatment for 1 week).
| ng/mL | Luliconazole Cream 1% |
|---|---|
| Predose | 0 ± 0 |
| 15 minutes postdose | 0 ± 0 |
| 30 minutes postdose | 18.11 ± 68.24 |
| 45 minutes postdose | 142.72 ± 298.29 |
| 1 hour postdose | 317.21 ± 401.97 |
| 1.5 hours postdose | 637.56 ± 509.09 |
| 2 hours postdose | 763.51 ± 607.80 |
| 2.5 hours postdose | 700.91 ± 423.74 |
| 3 hours postdose | 730.56 ± 349.10 |
| 4 hours postdose | 586.83 ± 309.83 |
| 6 hours postdose | 323.40 ± 219.50 |
| 8 hours postdose | 190.15 ± 154.82 |
| 10 hours postdose | 111.51 ± 102.30 |
| 24 hours postdose | 6.84 ± 10.01 |
Collected over Baseline up to Day 9. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Luliconazole Cream 1% | — | 0/20 (0%) | 4/20 (20%) |
| Event | Luliconazole Cream 1% |
|---|---|
| Muscle strainInjury, poisoning and procedural complications | 1/20 |
| Alanine aminotransferase increasedInvestigations | 1/20 |
| Aspartate Aminotransferase increasedInvestigations | 1/20 |
| Hemoglobin decreasedInvestigations | 1/20 |
| Back painMusculoskeletal and connective tissue disorders | 1/20 |
All participants who received at least 1 application of study drug and had at least 1 post-Baseline assessment.
| Age, Continuous(years) | Luliconazole Cream 1% |
|---|---|
| Mean | 45.05 ± 10.47 |
| Sex: Female, Male(Participants) | Luliconazole Cream 1% |
|---|---|
| Female | 1 |
| Male | 19 |
Ran from Feb 2015 to primary completion in Apr 2015, 1 month.
Results were first posted in Nov 2019, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luliconazole